As we welcome the fall season, it’s time for our September edition of Editors’ Picks, a monthly collection of articles hand-picked by the editors of the eight scientific journals published by the AACR. This...
The 12th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved wrapped up Monday in San Francisco. This year marked record attendance for the conference, as well...
In the effort to include more diverse patient populations in clinical trials, good intentions can easily go awry. Panelists in the “Addressing Advocacy at the Bench: Implementing Change” session held Sunday at The 12th...
The injustices come in many ways. A transgender woman is admitted to the hospital for cancer treatment. Her physicians decide to wean her from the hormones that have enabled her to live as a woman. ...
The 12th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved kicked off Friday evening in San Francisco with a passionate call to fight cancer disparities on...
Immunotherapy is a form of cancer treatment that helps a patient’s own immune system recognize and attack cancer cells. Research on different types of immunotherapy has exploded over the past decade, and such approaches...
Today, the American Association for Cancer Research (AACR) released its ninth annual Cancer Progress Report. The report highlights how research largely supported by federal investments in the National Institutes of Health (NIH) is spurring...
Cancer researchers often focus on developing novel treatments or combining therapies in new ways, all with the goal of lengthening survival for patients. But some cancer research has a different goal: to reduce the...
In recent decades, the cancer research community has made great strides by bringing new, targeted, safer, and longer-lasting treatments to patients dealing with a variety of cancers. While this achievement is truly remarkable and...
Pancreatic cancer is projected to become the second leading cause of cancer mortality in the United States by 2030. The prognosis for this disease remains grim: The overall five-year survival rate is lower than...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More